Based on the Avid Bioservices Inc stock forecast from 2 analysts, the average analyst target price for Avid Bioservices Inc is USD 12.00 over the next 12 months. Avid Bioservices Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Avid Bioservices Inc is Slightly Bearish, which is based on 5 positive signals and 7 negative signals. At the last closing, Avid Bioservices Inc’s stock price was USD 12.43. Avid Bioservices Inc’s stock price has changed by +0.57% over the past week, +0.73% over the past month and +97.62% over the last year.
No recent analyst target price found for Avid Bioservices Inc
No recent average analyst rating found for Avid Bioservices Inc
Company Overview Avid Bioservices Inc
Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California. Read Less
Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing serv...Read More
Frequently Asked Questions About Avid Bioservices Inc (CDMO) Stock
Based on ratings from 2 analysts Avid Bioservices Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on CDMO's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for CDMO is USD 12.00 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 12.
CDMO stock's Price/Earning ratio is 1,250.00.
Our analysis grades CDMO stock's Price / Earning ratio at F. This means that CDMO stock's Price/Earning ratio is above 99% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CDMO may be a overvalued for its sector.
The last closing price of CDMO's stock was USD 12.43.
The most recent market capitalization for CDMO is USD 0.79B.
Based on targets from 2 analysts, the average taret price for CDMO is projected at USD 12.00 over the next 12 months.
This means that CDMO's stock price may go down by -3.46% over the next 12 months.
We can't find any ETFs which contains Avid Bioservices Inc's stock.
As per our most recent records Avid Bioservices Inc has 371 Employees.
Avid Bioservices Inc's registered address is 14191 Myford Road, Tustin, CA, United States, 92780.
You can get more information about it from Avid Bioservices Inc's website at https://www.avidbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Avid Bioservices Inc (CDMO) Stock
Based on ratings from 2 analysts Avid Bioservices Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on CDMO's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for CDMO is USD 12.00 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 12.
CDMO stock's Price/Earning ratio is 1,250.00.
Our analysis grades CDMO stock's Price / Earning ratio at F. This means that CDMO stock's Price/Earning ratio is above 99% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CDMO may be a overvalued for its sector.
The last closing price of CDMO's stock was USD 12.43.
The most recent market capitalization for CDMO is USD 0.79B.
Based on targets from 2 analysts, the average taret price for CDMO is projected at USD 12.00 over the next 12 months.
This means that CDMO's stock price may go down by -3.46% over the next 12 months.
We can't find any ETFs which contains Avid Bioservices Inc's stock.
As per our most recent records Avid Bioservices Inc has 371 Employees.
Avid Bioservices Inc's registered address is 14191 Myford Road, Tustin, CA, United States, 92780.
You can get more information about it from Avid Bioservices Inc's website at https://www.avidbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CDMO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
